semaglutide bowel obstruction class action in west virginia louisiana Wegovy Lawsuit Lawyer louisiana glp-1 gi obstruction class semaglutide gastrointestinal obstruction class action

Key Insights from the Trial Extension Data: Participants who escalated to 7.2 mg lost 20.2% of their body weight, versus 15.6% with 2.4 mg in STEP 2

Hypoglycemia should be monitored for by the patient and clinician when semaglutide treatment is initiated and continued for type 2 diabetes mellitus (T2DM) and when used for weight reduction and maintenance

FDA-approved GLP-1 medications in the United States include both daily and weekly formulations

While compounded versions havent undergone the same trials, they contain the same active ingredient meaning they may offer similar benefits when sourced and administered appropriately

Compounded semaglutide has a significantly shorter usable life than brand-name alternatives

If you do not experience an immediate reduction in your appetite, do not feel discouraged or assume the treatment is failing